Max Robotics — Global Service Robot Directory + US Certification

About

Val Gebski is a leading biostatistician whose methodological expertise has profoundly shaped evidence-based practice in gynecologic oncology. His primary research areas include the design and analysis of randomized clinical trials, particularly in cervical and endometrial cancer, with a focus on surgical interventions and sentinel node biopsy. Gebski’s most impactful contribution is his pivotal role in the landmark 2018 study “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer,” which has garnered over 1,859 citations. This practice-changing trial demonstrated that minimally invasive surgery was associated with poorer survival outcomes compared to open surgery for early-stage cervical cancer, leading to revised global surgical guidelines. He also co-authored the foundational 2008 Phase III trial (161 citations) comparing laparoscopic or robotic radical hysterectomy with abdominal surgery, and more recently, the ENDO-3 protocol (2021) evaluating sentinel node biopsy in endometrial cancer. Gebski’s work is distinguished by rigorous statistical methodology that ensures reliable, reproducible results, directly influencing clinical decision-making. His contributions have earned him recognition as a key figure in Australia and New Zealand Gynaecological Oncology Group (ANZGOG) trials, cementing his legacy in advancing surgical oncology through robust evidence.